Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study

被引：0
|
作者：
Frost, A.
Buechert, M.
Unger, C.
Christensen, O.
Wagner, A.
Heinig, R. A.
Scheulen, M. E.
Strumberg, D.
Fasol, U.
Mross, K.
机构：
[1] Tumor Biol Ctr, Freiburg, Germany
[2] Univ Hosp Freiburg, Freiburg, Germany
[3] Bayer HealthCare Pharmaceut, West Haven, CT USA
[4] Bayer Schering Pharma AG, Berlin, Germany
[5] Bayer HealthCare, Wuppertal, Germany
[6] Univ Essen Gesamthsch, Sch Med, Essen, Germany
[7] Univ Hosp Bochum, Marienhosp Herne, Herne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2558
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [42] A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
    Hollebecque, A.
    Deutsch, E.
    Massard, C.
    Gomez-Roca, C.
    Bahleda, R.
    Ribrag, V.
    Bourgier, C.
    Lazar, V.
    Lacroix, L.
    Gazzah, A.
    Varga, A.
    de Baere, T.
    Beier, F.
    Kroesser, S.
    Trang, K.
    Zenke, F. T.
    Klevesath, M.
    Soria, Jean-Charles
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1530 - 1538
  • [43] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Wilson, Timothy R.
    Ware, Joseph A.
    Bohorquez, Sandra M. Sanabria
    Savage, Heidi M.
    Sampath, Deepak
    Salphati, Laurent
    Lin, Ray S.
    Jin, Huan
    Parmar, Hema
    Hsu, Jerry Y.
    Von Hoff, Daniel D.
    Baselga, Jose
    CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
  • [44] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
    Adjei, Alex A.
    LoRusso, Patricia
    Ribas, Antoni
    Sosman, Jeffrey A.
    Pavlick, Anna
    Dy, Grace K.
    Zhou, Xiaofei
    Gangolli, Esha
    Kneissl, Michelle
    Faucette, Stephanie
    Neuwirth, Rachel
    Bozon, Viviana
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 47 - 58
  • [45] Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors
    Kaneda, H.
    Okamoto, I.
    Satoh, T.
    Arao, T.
    Nishio, K.
    Sarashina, A.
    Konishi, K.
    Stopfer, P.
    Kaiser, R.
    Nakagawa, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 133 - 133
  • [46] Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
    Li, Huiping
    Liu, Rongrui
    Shao, Bin
    Ran, Ran
    Song, Guohong
    Wang, Ke
    Shi, Yehui
    Liu, Jihong
    Hu, Wenjing
    Chen, Fu
    Liu, Xiaoran
    Zhang, Gairong
    Zhao, Chuanhua
    Jia, Ru
    Wang, Quanren
    Rugo, Hope S.
    Zhang, Yifan
    Li, Guangze
    Xu, Jianming
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 370 - +
  • [47] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
    Alex A. Adjei
    Patricia LoRusso
    Antoni Ribas
    Jeffrey A. Sosman
    Anna Pavlick
    Grace K. Dy
    Xiaofei Zhou
    Esha Gangolli
    Michelle Kneissl
    Stephanie Faucette
    Rachel Neuwirth
    Viviana Bózon
    Investigational New Drugs, 2017, 35 : 47 - 58
  • [48] A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
    A. Hollebecque
    E. Deutsch
    C. Massard
    C. Gomez-Roca
    R. Bahleda
    V. Ribrag
    C. Bourgier
    V. Lazar
    L. Lacroix
    A. Gazzah
    A. Varga
    T. de Baere
    F. Beier
    S. Kroesser
    K. Trang
    F. T. Zenke
    M. Klevesath
    Jean-Charles Soria
    Investigational New Drugs, 2013, 31 : 1530 - 1538
  • [49] A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors'
    Kakolyris
    ONCOLOGY, 2006, 71 (3-4) : 203 - 203
  • [50] A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors
    Kakolyris, S
    Kouroussis, C
    Koukourakis, M
    Marvroudis, D
    Malas, K
    Vardakis, N
    Bozionelou, V
    Kalbakis, K
    Georgoulias, V
    ONCOLOGY, 2002, 63 (03) : 213 - 218
12345